Delivery Order SPE2DB22D9353-SPE2DB25FX2FS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order, issued on July 16, 2025, with an ultimate completion date of July 17, 2025, carries firm fixed-price terms and represents a direct procurement with no set-aside designation. This award falls under DMS Pharmaceutical Group's...
- On August 1, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, issued under contract number 4568977608, calls for the supply of Xtandi 40 mg capsules in quantities of 120 units, with an ultimate completion date of August 4, 2025. This award was made on a firm fixed-price basis with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules in quantities of 120 units. This $17,245.40 firm fixed-price delivery order was awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, and carries no set-aside designation. The order falls under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on May 28, 2025, with an ultimate completion date of May 29, 2025, represents a standard pharmaceutical procurement under the DLA's medical supply chain operations. The award carries no...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on July 22, 2025, is expected to be completed by July 23, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,622.72 on August 20, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order is funded by the Defense Logistics Agency (DLA) through the Medical Supply Chain division and is scheduled for completion by August 21, 2025, with performance taking place at the contractor's Park Ridge, Illinois...
- On July 28, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, numbered 4568915549, covers the supply of Xtandi 40 mg tablets (120-count units), an oncology medication used in the treatment of prostate cancer. This firm fixed-price delivery order is scheduled for completion by July 29, 2025, with performance to take place...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2FSDelivery Order
On September 26, 2025, the Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $51,736.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, identified as 4569610863, is for the supply of Xtandi 40 mg capsules in quantities of 120 units, with an ultimate completion date of September 29, 2025. This award carries no set-aside designation and represents a direct delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its status as a woman-owned small business to secure substantial contracts with the DLA. The company's IDC, valued at $499,999,999 and valid through November 2026, enables the agency to issue firm fixed-price delivery orders for an extensive portfolio of pharmaceutical products supporting military healthcare facilities worldwide. This particular delivery order for Xtandi, a prescription oncology medication, exemplifies the company's core business of distributing branded and generic prescription drugs to Department of Defense healthcare sites across the nation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $51.7k | 9/26/25 |